No black box warning on record for Aripiprazole

As of the latest FDA labeling reviewed, Aripiprazole (aripiprazole) does not carry a black box warning. Standard warnings and precautions still apply — see the full Aripiprazole medicine page for the complete safety profile.

Other warnings & precautions

Impulse Control Disorders — Critically Underrecognized: Aripiprazole has a unique and serious adverse effect of causing pathological impulse control disorders — compulsive gambling, hypersexuality, binge eating, compulsive shopping, and other behaviors — often without the patient recognizing the medicine as the cause. Risk is dose-dependent. Patients and caregivers must be warned about this risk before starting the medicine. Evaluate for new or unusual urges at each visit. Dose reduction or discontinuation typically resolves these behaviors.
Tardive Dyskinesia: Long-term use of any antipsychotic carries risk of tardive dyskinesia (TD) — potentially irreversible involuntary movements. Use at lowest effective dose for shortest duration. Evaluate periodically. Valbenazine (Ingrezza) or deutetrabenazine (Austedo) can treat TD if it develops.
Elderly Patients with Dementia-Related Psychosis — Black Box Warning: Elderly patients with dementia-related psychosis treated with antipsychotics have increased risk of death (cerebrovascular events, infections). Aripiprazole is not FDA-approved for dementia-related psychosis. Risk must be explicitly discussed with families.
Suicidality in Children and Adolescents — Black Box Warning (Antidepressant Adjunct Use): When used as adjunctive therapy for MDD in children and adolescents, aripiprazole carries the same black box warning as antidepressants about increased suicidal thinking and behavior. Monitor closely for worsening depression, unusual changes in behavior, or suicidality.
Metabolic Monitoring: Although aripiprazole has lower metabolic risk than olanzapine or quetiapine, regular monitoring of weight, fasting glucose, and lipids is recommended for all patients on atypical antipsychotics.
CYP Interactions — Dose Adjustment Required: Aripiprazole metabolism is significantly affected by CYP2D6 and CYP3A4 inhibitors/inducers. Dose adjustments are mandatory (50% reduction for inhibitors, doubling for inducers). Failure to adjust creates either toxicity or therapeutic failure.

Other warnings & precautions

Impulse Control Disorders — Critically Underrecognized: Aripiprazole has a unique and serious adverse effect of causing pathological impulse control disorders — compulsive gambling, hypersexuality, binge eating, compulsive shopping, and other behaviors — often without the patient recognizing the medicine as the cause. Risk is dose-dependent. Patients and caregivers must be warned about this risk before starting the medicine. Evaluate for new or unusual urges at each visit. Dose reduction or discontinuation typically resolves these behaviors.

Tardive Dyskinesia: Long-term use of any antipsychotic carries risk of tardive dyskinesia (TD) — potentially irreversible involuntary movements. Use at lowest effective dose for shortest duration. Evaluate periodically. Valbenazine (Ingrezza) or deutetrabenazine (Austedo) can treat TD if it develops.

Elderly Patients with Dementia-Related Psychosis — Black Box Warning: Elderly patients with dementia-related psychosis treated with antipsychotics have increased risk of death (cerebrovascular events, infections). Aripiprazole is not FDA-approved for dementia-related psychosis. Risk must be explicitly discussed with families.

Suicidality in Children and Adolescents — Black Box Warning (Antidepressant Adjunct Use): When used as adjunctive therapy for MDD in children and adolescents, aripiprazole carries the same black box warning as antidepressants about increased suicidal thinking and behavior. Monitor closely for worsening depression, unusual changes in behavior, or suicidality.

Metabolic Monitoring: Although aripiprazole has lower metabolic risk than olanzapine or quetiapine, regular monitoring of weight, fasting glucose, and lipids is recommended for all patients on atypical antipsychotics.

CYP Interactions — Dose Adjustment Required: Aripiprazole metabolism is significantly affected by CYP2D6 and CYP3A4 inhibitors/inducers. Dose adjustments are mandatory (50% reduction for inhibitors, doubling for inducers). Failure to adjust creates either toxicity or therapeutic failure.

Aripiprazole Black Box Warning

No black box warning on record for Aripiprazole

Other warnings & precautions

Aripiprazole Black Box Warning

No black box warning on record for Aripiprazole

Other warnings & precautions